Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million
Related news for (VCEL)
- Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
- Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
- Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
- vericel announces fda approval and commercial availability of maci arthro
- vericel announces fda approval of nexobrid for the treatment of pediatric patients with severe thermal burns